Left Main Coronary Artery Stenosis Clinical Trial
Official title:
eTryton Left Main Multi-center, Prospective, Non-randomized Single Arm Registry Evaluating the Tryton Side Branch Stent® for Treatment of de Novo CAD in Both LM and Circumflex (LCX) Coronary Arteries
The objective of this study is to demonstrate the clinical performance of the Tryton Side Branch Stent used in conjunction with a commercially available Drug Eluting Stent (DES) to treat de novo bifurcated lesions involving both the Left Main (LM) and Circumflex Coronary Artery(LCX).
The registry study will involve the collection of demographic and clinical data, including in-hospital and follow-up data to determine primary composite endpoint of MACE (Major Adverse Cardiac Events) at 9 months and secondary endpoints. Secondary endpoints are defined as successful deployment of the Tryton stent and main vessel DES within the target lesion, angiographic success <30% residual stenosis in LM and LAD/LCX by visual estimate and TIMI 3 flow post procedure, and freedom of in-hospital MACE. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04248777 -
Optical Coherence Tomography - Guided Protocol for Left Main Percutaneous Coronary Intervention
|
N/A | |
| Active, not recruiting |
NCT04111770 -
The OPTIMAL Randomized Controlled Trial
|
N/A | |
| Not yet recruiting |
NCT05650411 -
P2Y12 Inhibitor-based Single Antiplatelet Therapy After a Short DAPT vs. Conventional DAPT Following PCI With a Polymer-free Drug-coated Stent for Unprotected Left Main Coronary Artery Disease (ULTRA-LM)
|
N/A | |
| Active, not recruiting |
NCT03767621 -
Concordance Between FFR and iFR for the Assessment of Intermediate Lesions in the Left Main Coronary Artery. A Prospective Validation of a Default Value for iFR
|